UNSPSC 51351627: Estradiol valerate

This classification denotes a therapeutic estradiol with the molecular formula C23H32O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OKG364O896, chemically known as 3,17-epidihydroxyoestratriene but more generally known as estradiol valerate, which bears US NIH Compound Identifier 5757. European Medicines Agency schedules Estradiol valerate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07245MIG.

UNSPSC 51351627 Estradiol valerate is a Commodity code that captures state and local procurement of specific pharmaceutical active ingredients and formulations, including hormone replacement and therapeutic medications distributed through established supply chains to state agencies, counties, school districts, and other public health facilities. Recent activity shows state and local governments purchasing estradiol valerate and related generic pharmaceuticals through cooperative purchasing agreements that establish multi-year contracts with manufacturers, requiring submission of detailed product specifications including National Drug Codes, packaging configurations, dosage forms, and pricing across multiple net price and WAC-minus formats. The scope includes compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, with vendors maintaining relationships through authorized pharmaceutical wholesalers and demonstrating pricing flexibility to accommodate member-specific clinical and budget needs across participating jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for distribution to participating state and local government facilities including Oregon, with proposals due March 26, 2026. Vendors must supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with all products available in the marketplace by May 15, 2026 and resulting agreements effective July 1, 2026. The evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and remaining points on compliance with administrative data format requirements, EDI capability, and acceptance of a 3 percent administrative fee. Contract term is two years for new responders with optional extensions, while incumbent responders' amendments align with existing expirations through June 30, 2028. No specific set-aside designations or restrictions limiting responses to particular business classifications are identified in the available documentation.